Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 1, 2006, Pages 25-35

  Taylor Touré, Juliette ^a   Brandt, Nicole J ^b   Rhona Limcangco, M ^c   Briesacher, Becky A ^d  

^a BearingPoint   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

antiparkinson; antipsychotic; extrapyramidal syndromes; prescribing trends

Indexed keywords

AMANTADINE; AMITRIPTYLINE PLUS PERPHENAZINE; ANTIPARKINSON AGENT; BENZATROPINE MESILATE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; ENTACAPONE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LOXAPINE SUCCINATE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE MESILATE; PERPHENAZINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; THIORIDAZINE; TIOTIXENE; TOLCAPONE; UNINDEXED DRUG; ZIPRASIDONE;

AGED; ARTICLE; ASSISTED LIVING FACILITY; CLINICAL PRACTICE; CONTROLLED STUDY; DEMENTIA; DRUG UTILIZATION; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; NURSING HOME; PARKINSON DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

EID: 33747193519     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.03.003     Document Type: Article

References (45)

1. Casey D.E. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10 Suppl 3 (1995) 105-114
2. Avorn J., Monane M., Everitt D.E., et al. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 154 (1994) 1113-1117
3. Avorn J., and Gurwitz J.H. Principles of pharmacology. In: Cassel C., Cohen H.J., Larson E.B., et al. (Eds). Geriatric Medicine. 3rd ed. (1996), Springer-Verlag, New York, NY 55-70
4. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 3 (1993) 335-348
5. Hardie R.J., and Lees A.J. Neuroleptic-induced Parkinson's syndrome: Clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51 (1988) 850-854
6. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
7. Leucht S., Pitschel-Waltz G., Abraham D., and Kissfing W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35 (1999) 51-68
8. Devanand D.P., and Levy S.R. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 8 Suppl 1 (1995) S18-S27
9. Peabody D.A., Warner M.D., Whiteford H.A., and Hollister L.E. Neuroleptics and the elderly. J Am Geriatr Soc 35 (1987) 233-238
10. Shorr R.I., Fought R.L., and Ray W.A. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA 271 (1994) 358-362
11. Lasser R.A., and Sunderland T. Newer psychotropic medication use in nursing home residents. J Am Geriatr Soc 46 (1998) 202-207
12. Code of Federal Regulations. 42 CFR 483.60 (November 8, 2005)
13. Available at:. Centers for Medicare & Medicaid Services. Accessed. Medicare Current Beneficiary Survey (MCBS) (November 4, 2005)
14. Doshi J.A., Shaffer T., and Briesacher B.A. National estimates of medication use in nursing homes: Findings from the 1997 Medicare current beneficiary survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc 53 (2005) 438-443
15. Briesacher B.A., Limcangco M.R., Simoni-Wastila L., et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 165 (2005) 1280-1285
16. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 157 (1997) 1531-1536
17. De Dyn P.P., Rabheru K., Rasmussen A., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
18. Katz I.R., Jeste D.V., Mintzer J.E., et al., Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 60 (1999) 107-115
19. Street J.S., Clark W.S., Gannon K.S., et al., HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57 (2000) 968-976
20. Bates D.W., Spell N., Cullen D.J., et al., Adverse Drug Events Prevention Study. The costs of adverse drug events in hospitalized patients. JAMA 277 (1997) 307-311
21. Tune L.E. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 5 (2000) 149-153
22. Tune L., Carr S., Hoag E., and Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium. Am J Psychiatry 149 (1992) 1393-1394
23. Roe C.M., Anderson M.J., and Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 50 (2002) 836-842
24. Rochon P.A., and Gurwitz J.H. Optimising drug treatment for elderly people: The prescribing cascade. BMJ 315 (1997) 1096-1099
25. Kindermann S.S., Dolder C.R., Bailey A., et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience. Drugs Aging 19 (2002) 257-276
26. Avorn J., Bohn R.L., Mogun H., et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study. Am J Med 99 (1995) 48-54
27. Bouman W.P., and Pinner G. Use of atypical antipsychotic drugs in old age psychiatry. Adman Psycbiatr Treat 8 (2002) 49-58
28. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 60 Suppl 10 (1999) 5-14
29. Kennedy E., Song F., Hunter R., et al. Risperidone versus typical antipsychotic mediation for schizophrenia. Cochrane Database Syst Rep 2 (2000) CD000440
30. Duggan L., Fenton M., Dardennes R.M., et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2 (2000) CD001359
31. Chengappa K.N., Baker R.W., Kreinbrook S.B., et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 8 (1995) 12-15
32. Sajatovic M., Jaskiw G., Konicki P.E., et al. Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry 12 (1997) 553-558
33. Schillevoort I., de Boer A., Herings R.M., et al. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 35 (2001) 1517-1522
34. Baldessarini R.J., and Frankenburg F.R. Clozapine: A novel antipsychotic agent. N Engl J Med 324 (1991) 746-754
35. Davydov L., and Botts S.R. Clozapine-induced hypersalivation. Ann Pharmacother 34 (2000) 662-665
36. Spivak B., Adlersberg S., Rosen L., et al. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 12 (1997) 213-215
37. Richardson C., Kelly D.L., and Conley R.R. Biperiden for excessive sweating from clozapine. Am J Psychiatry 158 (2001) 1329-1330
38. Micromedex Healthcare Series Vol 121 (2004), Thomson Micromedex, Greenwood Village, Colo
39. Eckel F.M., and Crawley III H.K. A study of pharmacy services in North Carolina rest homes. J Am Pharm Assoc 11 (1971) 387-390
40. Spore D., Mor V., Larrat E.P., et al. Regulatory environment and psychotropic use in board-and-care facilities: Results of a 10-state study. J Gerontol A Biol Sci Med Sci 51 (1996) M131-M141
41. Mitty E.L. Policy perspectives: Assisted living and the role of nursing. Am J Nurs 103 (2003) 32-44
42. June. Briesacher B., Limcangco R., Simoni-Wastila L., and Doshi J. Trends in antipsychotic use in long-term care facilities: Report submitted to Centers for Medicare & Medicaid Services (2004)
43. Mechanic D., and McAlpine D.D. Use of nursing homes in the care of persons with severe mental illness: 1985-1995. Psycbiatr Serv 51 (2000) 354-358
44. Gilmer T.P., Folsom D.P., Hawthorne W., et al. Assisted living and use of mental health services among Medicaid beneficiaries with schizophrenia. J Ment Health Policy Econ 6 (2003) 59-65
45. Wagenaar D.B., Mickus M., Luz C., et al. An administrator's perspective on mental health in assisted living. Psychiatr. Serv 54 (2003) 1644-1646